Skip to main content

Interpace Biosciences to Review Strategic Alternatives

NEW YORK — Interpace Biosciences said on Thursday that it will undertake a strategic review of its business as it works to increase shareholder value following its recent delisting from the Nasdaq.

In February, Interpace announced that it had received a delisting notice from the Nasdaq for its failure to meet the exchange's minimum $2.5 million stockholders' equity requirement. At the time, the Parsippany, New Jersey-based company — which now trades on the Over-The-Counter Markets — also said that it was reorganizing in order to save $7.2 million in annual costs.

In April, Interpace reported that it was on track to meet this cost-cutting goal and that its revenues for the fourth quarter had more than doubled. On Thursday, the company said that it has raised its 2021 revenue guidance to between $42 million and $44 million from previous guidance of $38 million to $40 million.

Despite the expected revenue growth, Interpace said that its board believes its current stock price does not reflect the company's overall value. As a result, it is working with adviser Guggenheim Securities on a "review of a broad range of alternatives to enhance shareholder value."

During early morning trading, shares of Interpace were up $.60 to $8.50.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.